These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37107075)

  • 1. Linezolid Pharmacokinetics and Its Association with Adverse Drug Reactions in Patients with Drug-Resistant Pulmonary Tuberculosis.
    Padmapriyadarsini C; Solanki R; Jeyakumar SM; Bhatnagar A; Muthuvijaylaksmi M; Jeyadeepa B; Reddy D; Shah P; Sridhar R; Vohra V; Bhui NK
    Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Intake of Linezolid Elevates Drug Exposure and Reduces Drug Clearance and Elimination in Adults With Drug-Resistant Pulmonary Tuberculosis.
    Jeyakumar SM; Bhui NK; Singla N; Vilvamani S; Mariappan MV; Padmapriyadarsini C; Bhatnagar AK; Solanki R; Sridhar R
    Ther Drug Monit; 2023 Dec; 45(6):754-759. PubMed ID: 37296501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis.
    Padmapriyadarsini C; Vohra V; Bhatnagar A; Solanki R; Sridhar R; Anande L; Muthuvijaylakshmi M; Bhatia M; Jeyadeepa B; Taneja G; Balaji S; Shah P; Saravanan N; Chauhan V; Kumar H; Ponnuraja C; Livchits V; Bahl M; Alavadi U; Sachdeva KS; Swaminathan S;
    Clin Infect Dis; 2022 Jun; 76(3):e938-46. PubMed ID: 35767251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.
    Alghamdi WA; Al-Shaer MH; Kipiani M; Barbakadze K; Mikiashvili L; Kempker RR; Peloquin CA
    J Antimicrob Chemother; 2021 Mar; 76(4):1019-1024. PubMed ID: 33378452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination.
    Du J; Gao J; Yu Y; Li Q; Bai G; Shu W; Gao M; Liu Y; Wang L; Wang Y; Xue Z; Huo F; Li L; Pang Y
    Front Microbiol; 2021; 12():655653. PubMed ID: 34012425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
    Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
    Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining therapeutic trough ranges for linezolid.
    Alsultan A
    Saudi Pharm J; 2019 Dec; 27(8):1061-1063. PubMed ID: 31885465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linezolid-related adverse effects in the treatment of rifampicin resistant tuberculosis: a retrospective study.
    Cui D; Hu X; Shi L; Wang D; Chen G
    J Chemother; 2023 Sep; 35(5):404-410. PubMed ID: 36322121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure.
    Tsuji Y; Hiraki Y; Mizoguchi A; Hayashi W; Kamohara R; Kamimura H; Karube Y
    J Infect Chemother; 2008 Apr; 14(2):156-60. PubMed ID: 18622681
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin.
    Hiraki Y; Tsuji Y; Matsumoto K; Morita K; Kamimura H; Karube Y
    Am J Med Sci; 2011 Dec; 342(6):456-60. PubMed ID: 21681075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates.
    Zou L; Liu M; Wang Y; Lu J; Pang Y
    Tuberculosis (Edinb); 2015 Dec; 95(6):839-842. PubMed ID: 26395151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis.
    Lifan Z; Sainan B; Feng S; Siyan Z; Xiaoqing L
    Int J Tuberc Lung Dis; 2019 Dec; 23(12):1293-1307. PubMed ID: 31931914
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid-associated thrombocytopenia.
    Onita T; Ishihara N; Ikebuchi A; Yano T; Nishimura N; Tamaki H; Ikawa K; Morikawa N; Naora K
    J Clin Pharm Ther; 2022 Dec; 47(12):2041-2048. PubMed ID: 35893441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of cycloserine and linezolid during anti-tuberculosis treatment in Beijing, China.
    Zhu H; Guo SC; Liu ZQ; Wang B; Fu L; Chu NH; Lu Y
    Int J Tuberc Lung Dis; 2018 Aug; 22(8):931-936. PubMed ID: 29991404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.
    Zheng H; He W; Jiao W; Xia H; Sun L; Wang S; Xiao J; Ou X; Zhao Y; Shen A
    BMC Infect Dis; 2021 Apr; 21(1):330. PubMed ID: 33832459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.
    Alffenaar JW; Kosterink JG; van Altena R; van der Werf TS; Uges DR; Proost JH
    Ther Drug Monit; 2010 Feb; 32(1):97-101. PubMed ID: 20042919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput and wide-range simultaneous determination of linezolid, daptomycin and tedizolid in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry.
    Tanaka R; Kai M; Goto K; Ohchi Y; Yasuda N; Tatsuta R; Kitano T; Itoh H
    J Pharm Biomed Anal; 2021 Feb; 194():113764. PubMed ID: 33298382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linezolid in the treatment of extensively drug-resistant tuberculosis.
    Zhang L; Pang Y; Yu X; Wang Y; Gao M; Huang H; Zhao Y
    Infection; 2014 Aug; 42(4):705-11. PubMed ID: 24902521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.